FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret February 1, 2022 Radiotherapy Can Be Safely Omitted in Older Women with Low-Risk, HR-positive... February 24, 2023 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... August 1, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In... German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... Severe mental illness linked to low attendance at cancer screening
